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332Objective: The study objective was to evaluate the outcomes of surgery for active infective endocarditis with
aortic root abscess formation.
Methods:Between July 1996 and June 2009, 1161 patients underwent operation for aortic valve endocarditis, of
whom 172 had aortic root abscess. The infected valve was native in 96 patients and prosthetic in 76 patients.
Patients’ mean age ( standard deviation) and logistic EuroSCORE-predicted risk of mortality were 62  13
years and 23.1%  26%, respectively. Surgery was emergent in 96 patients (58%). The abscess involved
the aortic annulus in 90 patients (52%), the intervalvular fibrous body in 81 patients (47%), and the mitral an-
nulus in 21 patients (12%). Surgery consisted of radical resection of the abscess, reconstruction of the annulus
with patches, and valve replacement. Estimated mean follow-up was 4.0  0.3 years (range, 0–8.2 years).
Results: Thirty-day mortality was 25% (n ¼ 43) (prosthetic valve endocarditis vs native valve endocarditis,
35.5% vs 16.7%, P ¼ .005). Independent predictors of mortality were sepsis (odds ratio [OR], 3.6; 95%
confidence interval [CI], 1.2–10.7), renal insufficiency (OR, 3.3; 95% CI, 1.1–9.5), concomitant coronary artery
bypass grafting (OR, 2.8; 95% CI, 1.1–7.0), and prosthetic valve endocarditis (OR, 2.4; 95% CI, 1.1–5.6).
Survival at 1 and 5 years was 55%  4% and 50%  4%, respectively, and predicted by concomitant mitral
endocarditis (OR, 3.2; 95% CI, 1.3–8.2), sepsis (OR, 2.7; 95% CI, 1.6–4.5), renal insufficiency (OR, 1.9; 95%
CI, 1.1–3.4), and age (OR, 1.05; 95% CI, 1.02–1.07). Endocarditis recurred in 15 patients (8.7%) at a mean of
1.8  2.4 years postoperatively (39 days to 6 years).
Conclusions: The surgical treatment of aortic root abscess remains a challenge with relatively high perio-
perative morbidity and mortality, although long-term survival is satisfactory. (J Thorac Cardiovasc Surg
2012;143:332-7)Infective endocarditis (IE) is a disease characterized by
high morbidity and mortality. The incidence of IE in pa-
tients with prosthetic valves is 0.3% to 1.2% per year,
and such patients represent 1% to 5% of all patients with
IE.1 Prompt and appropriate antibiotic therapy is the main-
stay of treatment, but approximately one third of patients
with active IE and a high proportion of patients with
prosthetic valve endocarditis ultimately require surgery.
The virulence of the organism and whether the valve is na-
tive or prosthetic also determine whether the infection ex-
tends into the valve annulus and surrounding tissues
causing abscesses, fistulae, and false aneurysms.2 Periannu-
lar complications occur in approximately 9.8% to 40%,
with a higher rate in prosthetic valve endocarditis (PVE)
compared with native valve endocarditis (NVE), and ine Department of Cardiac Surgery, Heart Center, University of Leipzig,
ig, Germany.
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The treatment of this group of patients is a surgical chal-
lenge, particularly for those with complete aortic root
destruction and involvement of the intervalvular fibrous
body and mitral valve, and their contemporary risk and
long-term outcomes are ill defined.
The objectives of this study were to (1) describe the clin-
ical characteristics of patients undergoing surgery for para-
valvular abscesses complicating active aortic valve IE, (2)
compare the clinical differences between NVE and PVE,
(3) determine predictors of mortality and midterm survival,
and (4) determine rates of reoperation due to recurrent
endocarditis.
PATIENTS AND METHODS
This study was reviewed and approved by the institutional review board
at Herzzentrum, Universit€at Leipzig (Leipzig, Germany). During a 13-year
period between July 1996 and June 2009, 1161 patients underwent surgery
for aortic valve IE at our institution, of whom 172 (14.6%) had paravalv-
ular abscess formation. These patients are the subject of this report. Endo-
carditis was diagnosed according to the modified Duke criteria. Data were
collected from a computer registry maintained prospectively. Patients were
actively followed up annually by postal questionnaire and by contacting
the referring cardiologist or family physician, when required.
The surgical tenet of radical debridement of all infected tissue, drainage,
and exclusion of myocardial abscesses from the bloodstream and recon-
struction of annular defects with either bovine or autologous pericardiumery c February 2012
TABLE 1. Demographic and preoperative clinical characteristics
Total
N 172
Age (y) 62.5  13.8
Female 37 (21.5)
LVEF 30%–50% 53 (30.8)
LVEF<30% 17 (9.9)
Emergency 96 (55.8)
euroSCORE logistic 39  26
Sepsis 32 (18.6)
Pulmonary hypertension 17 (9.9)
CCF 35 (20.3)
NYHA III/IV 112 (67.1)
COPD 25 (14.6)
PVD 28 (16.3)
Neurologic dysfunction 25 (14.5)
Renal insufficiency 19 (11)
Diabetes mellitus 39 (22.7)
Cerebral embolism 21 (12.2)
Renal/splenic embolism 33 (19.2)
PVE 76 (44.2)
Data shown are numbers of cases (%), unless otherwise indicated. CCF, Congestive
cardiac failure; COPD, chronic obstructive pulmonary disease; euroSCORE, Euro-
pean System for Cardiac Operative Risk Evaluation; LVEF, left ventricular ejection
fraction; NYHA, New York Heart Association; PVD, peripheral vascular disease;
PVE, prosthetic valve endocarditis.
Abbreviations and Acronyms
ARA ¼ aortic root abscess
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
IE ¼ infective endocarditis
LCO ¼ low cardiac output
NVE ¼ native valve endocarditis
OR ¼ odds ratio
PVE ¼ prosthetic valve endocarditis
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The choice of valvular substitute was left to the discretion of the attending
surgeon.
Definitions
In accordance with the guidelines of the Society of Thoracic Surgeons,
early mortality was defined as all-cause mortality at 30 days. Operations
were considered emergent if performed within 24 hours of hospital admis-
sion for cardiovascular instability and urgent if performed during the index
hospital admission. Abscess formation was defined as necrotic tissue in the
aortic annulus or root, or as aortoventricular discontinuity. Sepsis was de-
fined as fever, leucocytosis, positive blood culture, hemodynamic instabil-
ity requiring vasopressors, or organ failure. Early endocarditis was defined
as occurring within 1 year of surgery. Complications from PVE were de-
fined as periannular abscess, thromboembolic events, sepsis, or a critical
preoperative state.
Statistical Analysis
Continuous variables are expressed as mean  standard deviation, and
categoric data are expressed as proportions. Categoric variables were com-
pared using the chi-square or Fisher exact test, and independent continuous
variables were compared by unpaired Student t test or Kruskal–Wallis test
as appropriate.We examined 29 potential preoperative risk factors for early
and late mortality by univariate and multivariate testing (Appendix 1).
Dichotomous adverse perioperative or postoperative outcome events
were analyzed using a univariate andmultivariate logistic regressionmodel
with backward stepwise elimination and are expressed as odds ratios (OR)
and 95% confidence intervals (CIs). Event-free survival was calculated by
Kaplan–Meier methods with 95% CI. Independent predictors of medium-
term survival were determined with Cox proportional hazards analysis.
All statistical analyses were performed using SPSS 17.0 (SPSS Inc,
Chicago, Ill).
RESULTS
This study included 172 patients undergoing surgery for
paravalvular abscesses complicating IE, of whom 96
(55.8%) had NVE and 76 (44.2%) had PVE (Table 1).
Emergent surgery was performed in 96 patients (56%).
Septic cerebral emboli were diagnosed in 21 patients
(12%), and septic renal or splenic emboli were diagnosed
in 33 patients (19.2%). Patients with PVE were older
than patients with NVE (64.9  13.8 vs 60.6  14.4 years,
P ¼ .04) and required more emergency operations (60.4%
vs 50.0%, P ¼ .01). The mean interval between operations
for patients with PVE was 4.7 6.0 years (range, 14 days to
28.3 years).The Journal of Thoracic and CaMicrobiologic data were available for 122 patients, with
the most common organism being Staphylococcus in 49
(40.2%), Streptococcus in 28 (23%), and Enterococcus in
18 (14.8%); cultures were negative in 17.2% of patients
(n ¼ 21) (Table 2). Streptococcal species tended to be
more common in patients with NVE (19% vs 9%,
P¼ .08); however, gram-negative infections were more fre-
quent in patients with PVE (5.2% vs 0%, P ¼ .04).
The aortic root abscess (ARA) localization and other
operative details are presented in Table 3. The paravalvular
abscess extended into the intervalvular fibrous body in 81
patients (47.1%) and the mitral annulus in 21 patients
(12.2%). Coronary ostia destruction was more commonly
observed in patients with PVE (14.5% vs 2.1%,
P ¼ .05). Perforation into the left atrium, however, was
more often seen in patients with NVE (10.5% vs 2.1%,
P ¼ .01). Concomitant mitral endocarditis was present in
47 patients (NVE 42% vs PVE 9.2%, P<.01), and a further
9 patients had nonendocarditic mitral disease. Aortic aneu-
rysms were present in 25 patients (14.5%).
Operative Details and Postoperative Complications
Isolated aortic valve or root surgery was performed in 70
patients (40.7%) and combined with concomitant proce-
dures in 102 patients (59.3%). Mechanical valves were
used in 18 patients (10.5%), and homografts were used in
13 patients (7.5%). Double patch reconstruction of the
intervalvular fibrous body with mitral and aortic valve/
root replacement was necessary in 27 patients (15.7%).rdiovascular Surgery c Volume 143, Number 2 333
TABLE 2. Microbiologic data*
Organism
Staphylococcus species 49 (40.5)
Staphylococcus aureus 31 (25.4)
S epidermidis 9 (7.4)
Coagulase-negative 1 (0.8)
Other Staphylococcus 8 (6.5)
Streptococcus species 28 (22.9)
Streptococcus bovis 4 (3.3)
Other Streptococcus 24 (19.6)
Enterococcus species 18 (14.7)
Enterococcus faecalis 14 (11.5)
Other enterococcus 4 (3.3)
Gram-negative 4 (3.3)
Escherichia coli 3 (2.4)
Proteus 1 (0.8)
Candida 2 (1.6)
Culture negative 21 (17.2)
Data shown are numbers of cases (%). *Data available for 122 patients.




Aortic valve annulus 90 (52.3)
LVOT 7 (4.1)
Intervalvular fibrous body 81 (47.1)
Mitral annulus 21 (12.2)
Destruction of coronary ostia 13 (7.6)
Perforation into
Left atrium 10 (5.8)
Right atrium 6 (3.5)
Right ventricle 7 (4.1)
Procedure
AVR 31 (18.0)
AVR with patch reconstruction 44 (25.5)
ARR 49 (28.4)
ARR with patch reconstruction 21 (12.2)
Reconstruction of IVFB 27 (15.6)
Concomitant surgery 102 (59.3)
MV replacement 39 (22.6)
MV reconstruction 18 (10.4)
CABG 42 (24.4)
Aortic surgery 25 (14.5)
TV surgery 10 (5.8)
Operative time (min) 292  130
CPB time (min) 196  104
Crossclamp time (min) 126  54
ARR, Aortic root reconstruction; AVR, aortic valve replacement; CABG, coronary ar-
tery bypass grafting; CPB, cardiopulmonary bypass; IVFB, intervalvular fibrous
body; LVOT, left ventricular outflow tract; MV, mitral valve; TV, tricuspid valve.
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reconstruction with aortic root replacement (42.1% vs
17.7%, P < .01) or reconstruction of the intravalvular
body (26.3% vs 7.3%, P<.01), and had a higher incidence
of concomitant coronary artery bypass grafting (CABG)
(32.9% vs 17.7%, P<.01) and aortic surgery (21.1% vs
9.4%, P<.01) (Table 3).
As expected, operative time (360 130minutes vs 238
101 minutes, P<.01), cardiopulmonary bypass time (244
114 minutes vs 157 76minutes, P<.01), and aortic cross-
clamp time (148  57 minutes vs 108  45 minutes,
P< .01) were significantly longer in patients with PVE.
In comparison with patients with NVE, patients with PVE
were more likely to have postoperative low cardiac output
(LCO) syndrome, to require reoperation for bleeding, or
to have gastrointestinal complications (Table 4).TABLE 4. Postoperative complications
Total NVE PVE P
n 172 96 76
LCO syndrome 39 (22.7) 12 (12.5) 27 (35.5) <.001
Sepsis 22 (12.8) 12 (12.5) 10 (13.2) .8
Reoperation for bleeding 28 (16.3) 11 (11.5) 17 (22.4) .055
Pacemaker implantation 30 (17.4) 15 (15.6) 15 (19.7) .5
Pneumonia 29 (16.9) 15 (15.6) 14 (18.4) .6
Stroke 8 (4.7) 5 (5.2) 3 (3.9) .7
Renal failure 47 (27.3) 25 (26.0) 22 (28.9) .6
GI bleeding 10 (5.8) 8 (8.3) 2 (2.6) .3
Ileus 9 (5.2) 1 (1.0) 8 (10.5) .007
30-d mortality 43 (25) 16 (16.7) 27 (35.5) .005
Data shown are numbers of cases (%).GI,Gastrointestinal; LCO, low cardiac output;
NVE, native valve endocarditis; PVE, prosthetic valve endocarditis.Risk Factors for Mortality
The early mortality for the entire cohort was 25%
(n ¼ 43). Patients with PVE had a higher mortality com-
pared with patients with NVE (35.5% vs 16.7%, P<.01).
Likewise, patients with concomitant mitral valve endocardi-
tis had higher mortality compared with those without
(36.2% vs 20%,P¼ .04), and patients undergoing concom-
itant CABG higher mortality compared with those not
undergoing CABG (47% vs 21.5%, P<.01). Ten patients
died of LCO (n¼ 8; 18.6%) and bleeding (n¼ 2, 4.6%) in-
traoperatively. In the remaining 33 patients, causes of early
death were LCO (n ¼ 15, 35.0%), sepsis (n ¼ 5, 11.6%),
hemodynamic instability with bleeding (n¼ 3, 7.0%), mul-
tiorgan failure (n ¼ 3, 7.0%), ileus (n ¼ 4, 9.3%), neuro-
logic complications (n¼ 1, 2.3%), and other (n¼ 2, 4.6%).
Univariate analysis of risk factors for mortality identified
sepsis (OR, 5.5; 95% CI, 2.4–12.6; P < .01), renal334 The Journal of Thoracic and Cardiovascular Surginsufficiency (OR, 4.1; 95% CI, 1.6–10.4; P<.01), preop-
erative New York Heart Association functional class IV
(OR, 3.2; 95% CI, 1.5–6.8; P ¼ .01), congestive cardiac
failure (OR, 3.1; 95% CI, 1.4–6.9; P<.01), CABG (OR,
3.1; 95% CI, 1.2–7.7; P ¼ .01), prior aortic valve surgery
(OR, 2.8; 95% CI, 1.4–5.6; P<.02), and mitral valve endo-
carditis (OR, 2.2; 95% CI, 1.1–4.5; P ¼ .03). Multivariateery c February 2012
FIGURE 1. A, Kaplan–Meier survival for patients with NVE and PVE. B, Kaplan–Meier survival for patients with and without mitral valve endocarditis.
C, Freedom from endocarditis stratified by valve substitute. NVE, Native valve endocarditis; PVE, prosthetic valve endocarditis.
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P< .01), renal insufficiency (OR, 3.3; 95% CI, 1.1–9.5;
P ¼ .02), CABG (OR, 2.8; 95% CI, 1.1–7.0; P ¼ .01),
and PVE (OR, 2.4; 95% CI, 1.1–5.6; P ¼ .03) as indepen-
dent predictors of mortality.Predictors of Long-Term Survival
Follow-upwas 100% completewith an estimatedmean of
4.0  0.3 years (range, 0–8.2 years) and a total of 248.8
patient-years. Survival at 1, 3, and 5 years was 55% 
4%, 50% 4%, and 50% 4%, respectively, with no sig-
nificant difference between NVE and PVE groups (log rank
P ¼ .17) (Figure 1, A). Survival was not significantly influ-
enced by valve substitute (log rank P ¼ .22) (mechanical,
tissue, or homograft) or surgical procedure performed (log
rank P¼ .06) (aortic valve replacement patch reconstruc-
tion vs aortic root reconstruction  patch reconstruction).
Survival of patients with concomitant mitral endocarditis
was significantly worse than survival of patients without
concomitant mitral endocarditis (Figure 1, B) (log rankThe Journal of Thoracic and CaP ¼ .002), but there was no significant effect on survival
of the need for concomitant CABG (log rank ¼ 0.1). Inde-
pendent predictors of long-term survival were mitral valve
endocarditis (OR, 3.2; P ¼ .01), sepsis (OR, 2.7; P<.01),
renal insufficiency (OR, 1.9; P ¼ .02), and age (OR, 1.05;
P<.01).Freedom From Recurrent Endocarditis
The 5-year freedom from recurrent endocarditis was
80%  4%. Fifteen patients underwent surgery for recur-
rent endocarditis during follow-up (early in 10, late in 5),
8 of whom had an aortic valve replacement and 7 of
whom had an aortic root replacement at the primary opera-
tion. Early endocarditis was diagnosed between 39 and 245
days postoperatively, and late endocarditis was diagnosed
between 2.4 and 6 years postoperatively. Although no cases
of recurrent endocarditis occurred in patients who received
a homograft, we were unable to demonstrate a statistically
significant effect of implanted valve type on recurrent infec-
tion (Figure 1, C, log rank ¼ 0.76), possibly because of therdiovascular Surgery c Volume 143, Number 2 335
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effect of operation type on freedom from endocarditis (log
rank ¼ 0.7).
DISCUSSION
Our study presents 13-year single-center results in a group
of high-risk patients undergoing surgery for active aortic
NVE and PVE complicated by paravalvular abscess forma-
tion. The results confirmprevious reports ofworse outcomes
for patients with PVE compared with NVE with regard to
higher operative mortality and morbidity, and poorer mid-
term survival. Patientswith sepsis or renal failure and requir-
ing concomitant CABG also had higher risk. Long-term
survival was adversely affected by concomitant mitral valve
endocarditis rather than prosthetic aortic valve involvement,
but also by sepsis, renal failure, and age, and was reasonable
considering how ill the patients were.
Theoverall operativemortality inour series of paravalvular
abscesseswas 25%. Reportedmortality rates vary from3.7%
to 31%,2,4,5with differences beingmultifactorial.Most of our
patients were treated initially in referring hospitals, wherewe
had no input regardingmedical management, and referred for
surgery only after medical management failed, often in
cardiac failure with multiorgan dysfunction. The evidence
is clear that early surgery in active endocarditis with
complications such as paravalvular abscesses leads to better
outcomes.6-8
PVE, which is known to carry a higher mortality (>2
times in our series) compared with NVE, was present in
more than 44% of our patients. Periannular complications
are often associated with both prosthetic valves and Staph-
ylococcal infection, and in our study Staphylococcus was
the most common organism causing abscess formation.9,10
This organism has been identified as a predictor of mortality
in some,3 but not all,2 studies, our data being concordant
with the latter.
In commonwith other studies, our study identified sepsis,2
concomitant CABG,11,12 and renal failure5,13 as predictors of
mortality. Numerous other predictors of mortality have been
identified, including preoperative ventilation,14 persistent fe-
ver despite antibiotic treatment,14 poor ejection fraction,15
mitral involvement,2 neurologic impairment,5 and age.10
Despite high operative mortality and morbidity, the long-
term survival was satisfactory (46% at 6 years) considering
how ill the patients were before surgery and the complexity
of the operative procedures involved, as also demonstrated
by data from Toronto9 and Berlin.16 Long-term survival is
known to be adversely affected by age, septic shock, PVE,
impaired ventricular function, and recurrent infections.9,17
Our data show that concomitant mitral valve involvement
and renal failure also predicted midterm mortality.
The choice of the optimal valve is a subject of debate but
is not a substitute for radical debridement and extirpation of
all infected tissues. Many surgeons believe that aortic336 The Journal of Thoracic and Cardiovascular Surghomografts are the best valve substitute for patients with
ARA because of ease of handling and the ability to use
the anterior mitral leaflet of the homograft to patch defects
remaining from resection of abscesses.2 The 10-year free-
dom from recurrent endocarditis of homografts has been
reported as 90% to 95%.18,19 However, in our series,
homografts were used in only 13 patients (7.5%), similar
to 10% reported in the series by David and colleagues.2
Our mainstay for reconstructing annular defects was autol-
ogous or bovine pericardial patch. We found no statistical
difference on freedom from recurrent endocarditis of the
implanted valve type, although this may well represent
a type II error. In fact, one could reasonably come to this
conclusion on examination of the difference in the hazard
curves shown in Figure 1, C. The choice of valve substitute
also did not affect long-term survival, which is more likely
influenced by numerous other factors.20 However, the use of
homografts is limited by patient age, with only 47% of pa-
tients aged less than 20 years being free from structural
valve deterioration after 15 years.21 The median time to re-
operation for structural valve deterioration varies from 23
years in a 65-year-old patient to approximately 12 years
in a 25-year-old patient.22
The 5-year freedom from endocarditis in our study was
80%, with the highest risk of recurrence in the first 8
months postoperatively (66% of patients). In 7 of 15 pa-
tients with recurrent endocarditis, Staphylococcus was the
original organism, but Staphylococcal infection was not
found to be a predictor of recurrence (P ¼ .1). There were
no recurrences between 8 months and 2.4 years. These
data confirm the findings of previous studies that the risk
of recurrent valve infection with a bioprosthesis or mechan-
ical prosthesis is highest early after surgery and then rea-
ches a low level of constant hazard.23 In contrast, the
homograft has a low constant hazard level without early
increased risk after surgery.
Although many reports have addressed outcomes for
ARAs,2,5,16,18 there are comparatively little data on
combined aortic and mitral abscesses. The intervalvular
fibrous body was involved in 47% of our patients, and the
mitral annulus was involved in 12% of our patients.
Resection of the intervalvular fibrous body is a difficult
procedure and associated with high operative mortality,
but we believe it is necessary when involved. The
treatment of patients with concomitant mitral valve
endocarditis is also challenging and, as our and Gabbieri
and colleagues’ data17 demonstrate, associated with higher
mortality and worse long-term survival. The German Heart
Center in Berlin reported on 53 patients with double valve
endocarditis complicated by ARA with a 29% mortality
predicted by septic shock and severe aortic root destruc-
tion.15 Likewise, the University of Toronto group reported
90 patients with double-valve endocarditis, of whom 51%
had an ARAwith 15.6% in-hospital mortality.24ery c February 2012




Several limitations of our studyhave to be outlined. First, it
is retrospective and nonrandomized, butwe think this is a rea-
sonable approach to assess predictors of outcome in one of
the largest published series of surgically treated patients
withARAcomplicating active aortic valve endocarditis. Sec-
ond, such a long-term experiencewill inevitably be biased by
a learning curve, intersurgeon variability, and variations in
perioperative medical and surgical management.
CONCLUSIONS
The surgical treatment of active aortic valve endocarditis
with ARA formation is challenging because mortality and
morbidity remain high, particularly for prosthetic valve
involvement, although long-term survival is satisfactory
considering the patients’ illness severity.
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Cardiovasc Surg. 2009;138:69-75.APPENDIX 1. Preoperative factors used in univariate,
multivariate, and Cox regression analyses
Age, sex, body mass index, chronic pulmonary disease,
peripheral vascular disease, previous stroke or transient
ischemic attack, chronic renal insufficiency, diabetes melli-
tus, syncope, history of myocardial infarction, unstable
angina, cardiogenic shock, New York Heart Association
functional class (I–IV), left ventricle ejection fraction
(%), pulmonary hypertension, sepsis, surgical timing (elec-
tive, urgent, and emergency), active endocarditis, staphylo-
coccal infection previous surgery, type of implanted valve,
biological valve dysfunction or degeneration, paravalvular
leak, mechanical valve dysfunction (thrombosis or
fibrosis), ascending aortic aneurysm, mitral valve endocar-
ditis (native mitral valve endocarditis and prosthesis mitral
valve endocarditis), CABG, tricuspid valve disease, extent
of endocarditis, that is, involvement (aortic valve annulus,
intervalvular body, left ventricular outflow tract, left atrial
perforation, right atrial perforation, right ventricle
perforation), and septic cerebral and renal/splenic
embolism.rdiovascular Surgery c Volume 143, Number 2 337
